Dr. Sylvia Adams with a patient.
Photo: 嘿嘿视频 Staff
Triple-negative breast cancer聽is one of the most aggressive forms of the disease and is often diagnosed at a later stage. Options for treatment of the disease are limited, but a new is showing promising outcomes.
This study finds that women with triple-negative breast cancer lived longer if they received a combination of immunotherapy and chemotherapy compared with chemotherapy alone. These results are expected to be practice changing for other people diagnosed with the disease.
Sylvia Adams, MD, a director of clinical research at 嘿嘿视频鈥檚 Perlmutter Cancer Center and associate professor of medicine in the , spoke with The New York Times about the groundbreaking clinical trial that she led in the United States. 鈥淭his is truly a game changer,鈥 she says.
Read more from .
